Blueprint Precision Therapy, Finalist for Innovative Treatment spree for chronic granulocytic leukemia

Last week, the FDA issued four orphan drug qualifications, including the ret inhibitor pralsetinib developed by Bluerpint Medicines, and other innovative treatments in the study that include the treatment of chronic granulocytic leukemiaDrug:P ralsetinib (BLU667)research and development enterprise: Blueprint Medicinestreatment of disease: RET fusion, RET mutation and TRKC-positive low-differentiated thyroid cancer, undifferentiated or transsexual thyroid cancer, thyroid myelin cancer and localadvanced or metastatic follicles Profile of the sex or papilloma thyroid cancer:Pralsetinib (BLU667) is an oral (once daily) targeted, highly selective, targeted, carcinogenic RET variant developed by Blueprint Medicines, which Istoid Pharmaceuticals has exclusive development and commercialization of the drug in Greater ChinaBlueprint Medicines is undergoing clinical development of pralsetinib to treat patients with RET variants of non-small cell lung cancer, thyroid myelin carcinoma and other solid tumorsIn preclinical studies, pralsetinib consistently showed sub-nanomole levels for the most common RET gene fusion, activation mutations, and drug-resistant mutationsOf these, the selectivity of PRalsetinib to RET is 90 times higher than that of VEGFR2In addition, the selectivity of pralsetinib to RET was significantly improved compared to approved multikinase inhibitorsBy inhibiting primary and secondary mutations, pralsetinib is expected to overcome and prevent the occurrence of clinical resistanceThis treatment is expected to achieve long-lasting clinical remission and good safety in patients with different RET variantsDrug: amitriptylineresearch and development enterprise : Algo Therapeutix treatment of disease
: erythromelalgia introduction : erythromycin limb pain is an unexplained end-of-end vascular destrophy dysfunction disorder, clinically characterized by limb skin redness, swelling, pain, heat, mostly occurs in both feet Aminelinen is a tricyclic anti-depressive drug that affects chemicals that may be unbalanced in the brains of depressed patients They can be used in low doses to reduce pain Drug : Human Placent Extract research and development company :P lakouss Therapeutics treatment of disease : prevention of early (premature small intestine colitis) in premature babies (less than 34 weeks of age) profile :P lakousouss for a human biologics company engaged in repair and regenerative healing, the company has established a safe and effective treatment platform for the manufacture of biological therapy drugs from the human placenta after childbirth The drug promotes and maintains healing by coordinating fetal development with placental cytokines and growth factors, and can also be used to treat osteoarthritis Drug : Nilotini oral dissociation tablets research and development company : Nanocopoeia treatment of disease : Chronic granulocytic leukemia introduction : Chronic granulocytic leukemia (CML) is a malignant bone marrow proliferative tumor that occurs in pluripotent hematopoietic stem cells, characterized by a significant increase in peripheral blood cell cells, in the affected cell line, ph chromosome and /or BCR-ABL fusion gene fusion Nilotinib is a selective tyrosine kinase inhibitor targeting BCR-ABL kinase, c-KIT, and platelet-derived growth factor receptors (PDGFR); Nilotinib inhibits the proliferation of BCR-ABL-mediated leukemia cell lines by binding to the atP binding site of BCR-ABL and inhibiting the activity of tyrosine kinase